December 2016
-
Insmed Incorporated has announced the appointment of Clementia Pharmaceuticals President and CEO Clarissa Desjardins to its board of directors and the promotions of Roger Adsett to Chief Operating Officer and Drayton Wise to Senior VP, Head of United… Read more . . .
-
According to Adherium, the company has received $1.1 million in a second round of secured debt note financing, and the subscriber for this round is new strategic investor Trudell Medical Limited, parent company of respiratory… Read more . . .
-
AZTherapies has named Ernest D. Penachio to the newly created position of VP of Manufacturing Operations and CMC to oversee clinical and pre-commercial manufacturing, scale-up, and CMC content development for the company’s ALZT-OP1 inhaled cromolyn/oral… Read more . . .
-
Device maker Iconovo and particle engineering specialist CrystecPharma have announced a non-exclusive collaboration agreement for development of dry powder inhalers. The companies say that they plan to develop engineered particles using CrystecPharma’s modified supercritical anti-solvent… Read more . . .
-
Many of the winners at this year’s CPhI Pharma Awards, held on November 5 at the 2019 CPhI Worldwide meeting in Frankfurt, Germany, offer significant expertise in inhaled and nasal drug delivery, including Lonza, which… Read more . . .
-
Kind Consumer has announced the UK launch of its breath activated Voke 0.45mg nicotine inhaler, which will be available to consumers by direct online purchase at a price of £11.99. The Voke inhaler was approved by… Read more . . .
-
Inhaled drug developer Pulmatrix has announced the appointment of Nocion Therapeutics CEO Rick Batycky to its board of directors. Batycky was a founder of Civitas Therapeutics, which developed Inbrija inhaled levodopa and which was acquired by Acorda… Read more . . .
-
MannKind Corporation said that it has reached the second milestone in its development of Treprostinil Technosphere (“TreT”), a dry powder formulation of treprostinil for inhalation that the company is developing for the treatment of pulmonary arterial… Read more . . .
-
Insmed has announced the appointment of Martina Flammer as Chief Medical Officer, effective mid-December 2019. Flammer was most recently Senior VP Customer Value at Boehringer Ingelheim and her previous positions include VP Medicine, Regulatory Affairs… Read more . . .
-
Aptar has announced its acquisition of Noble International, which specializes in training devices and patient onboarding for drug delivery devices, including inhalers. Noble makes respiratory trainers for both MDIs and DPIs with a variety of… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK